NHS Adds Mirvetuximab Soravtansine: Targeted Ovarian Cancer Therapy That Extends Life and Reduces Side Effects

A new targeted treatment for certain hard‑to‑treat ovarian cancers, mirvetuximab soravtansine, is now funded by the NHS. The drug delivers chemotherapy directly to cancer cells, reducing systemic side effects and improving quality of life while extending average survival.

How the Drug Works

Mirvetuximab soravtansine is an antibody–drug conjugate: a potent chemotherapy compound chemically linked to an antibody engineered to recognise folate receptor alpha, a protein found on the surface of some ovarian cancer cells. The antibody binds to cancer cells, is taken inside them and then releases its toxic payload, killing the tumour while sparing much of the healthy tissue. Because of this targeted delivery it is often described as a "biological missile" or a "Trojan horse" therapy.

Clinical Benefit

Clinical data show the treatment increases average survival from 12.8 months with standard chemotherapy to 16.5 months with mirvetuximab, and is associated with improved quality of life. Side effects tend to be less debilitating than conventional chemotherapy: many women report lower levels of fatigue and nausea, and some are able to keep their hair. The therapy is given by infusion every three weeks, compared with more frequent schedules for some standard regimens.

Patricia having her infusion of the drug [Patricia Hill]

Patient Experience

Patricia Hill, 64, from north London, who started mirvetuximab in January after multiple rounds of chemotherapy, described the change as "like night and day" and said the treatment had given her "a lot of my life back." She reported feeling less tired and nauseous, and has been able to enjoy West End shows, restaurants, the Chelsea Flower Show and visits to family in Ireland.

"It actually opens up a lot of possibilities — you can actually go and do a lot more than you would normally do," Patricia said.

Jenny Green, 71, from Hertfordshire, who participated in the clinical trials, said she tolerated the drug "very well, with hardly any side effects," and reported scans showing shrinking nodules and improved blood results.

Who Can Access It

NICE (the National Institute for Health and Care Excellence) has approved mirvetuximab soravtansine for ovarian, peritoneal and fallopian tube cancers that are no longer responding to chemotherapy and that express folate receptor alpha. NHS England has confirmed it will fund the treatment. Wales and Northern Ireland generally follow the same decisions; Scotland considers its own approvals.

[BBC]

Health officials estimate that up to 400 patients per year in England could be eligible. Around 30–40% of tumours that are resistant to standard chemotherapy display the folate receptor alpha marker and may be suitable for this treatment.

Expert and Charity Reactions

Clinicians and patient groups have welcomed the decision. Dr Rowan Miller, who led trials at UCLH, called it the result of a 20‑year search for better options for this patient group. Professor Ruth Plummer described it as the "most significant breakthrough" in treating these hard‑to‑treat ovarian cancers in over two decades. Ovacome and Target Ovarian Cancer said the NHS availability is an important step for women with platinum‑resistant disease and their families.

Development and Manufacturer

Mirvetuximab soravtansine was developed by AbbVie. Its approval offers the first new targeted treatment option for this subgroup of ovarian cancers in 20 years, combining improved survival with a more tolerable side‑effect profile for many patients.

What This Means

For eligible women, mirvetuximab soravtansine brings a meaningful increase in survival and, importantly, a better quality of life compared with many conventional chemotherapy options. Clinicians will identify patients through testing for folate receptor alpha to determine suitability.